Gentzler

The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies

National Cancer Institute · UM1

PI · $13.2M · Johns Hopkins University

University of Virginia Cancer Center Support Grant

National Cancer Institute · P30

Project lead · $334.4K · University of Virginia

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Principal investigator · Recruiting · Phase 2

Ryan Gentzler, MD

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Principal investigator · Active not recruiting

University of Virginia

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Principal investigator · Completed · Phase 1

National Cancer Institute (NCI)

Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

Study chair · Not yet recruiting · Phase 3

PrECOG, LLC.